Gene therapy for krabbe disease: researchers track Long-Term safety and progress
NCT ID NCT06308718
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This study follows up with Krabbe disease patients who previously received FBX-101 gene therapy in earlier clinical trials. The goal is to check for long-term side effects and see how well their motor skills are maintained over time. Only 2 participants were enrolled, and no new treatments are given—just observation and monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRABBE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Hospitals - Michigan Medicine
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.